8. Références suite (351-695)

351. Critchley IA, Douglas LJ (1987). Role of glycosides as epithelial cell receptors for Candida albicans. J Gen Microbiol 133:637-643.

352. Tosh FD, Douglas LJ (1992). Characterization of a fucosidebinding adhesin of Candida albicans. Infect Immun 60:4734-4739.

353. Brassart D, Woltz A, Golliard M, Neeser J-R (1991). In vitro inhibition of adhesion of Candida albicans clinical isolates to human buccal epithelial cells by Fuco1->2Gal-bearing complex carbohydrates. Infect Immun 59:1605-1613.

354. Yu L, Lee KK, Ens K, Doig PC, Carpenter MR, Staddon W, et al. (1994). Partial characterization of a Candida albicans fimbrial adhesin. Infect Immun 62:2834-2842.

355. Holmes AR, Gopal PK, Jenkinson HF (1995b). Adherence of Candida albicans to a cell-surface polysaccharide receptor on Streptococcus gordonii. Infect Immun 63: 1827-1834.

356. Kanbe T, Cutler JE (1994). Evidence for adhesin activity in the acid-stable moiety of the phosphomannoprotein cell wall complex of Candida albicans. Infect Immun 62:1662-1668.

357. Cannon RD, Nand AK, Jenkinson HF (1995). Adherence of Candida albicans to human salivary components adsorbed to hydroxylapatite. Microbiol 141:213-219.

358. Hoffman MP, Haidaris CG (1994). Identification and characterization of a Candida albicans-binding proteoglycan secreted from rat submandibular salivary glands. Infect Immun 62:828-836.

359. Justin M. O’Sullivan, Richard D. Cannon, Patrick A. Sullivan and Howard F. Jenkinson, (1997). Identification of salivary basic proline-rich proteins as receptors for Candida albicans,  adhesion Microbiology (1997), 143, 341–348

360. Nikawa H, Hayashi S, Nikawa Y, Hamada T, Samaranayake LP (1993). Interactions between denture lining material, protein pellicles and Candida albicans. Arch Oral Biol 38:631-634.

361. Jenkinson HF, Lala HC, Shepherd MG (1990). Coaggregation of Streptococcus sanguis and other streptococci with Candida albicans. Infect Immun 58:1429-1436.

362. L. Li, S. Redding, and A. Dongari-Bagtzoglou. Candida glabrata, an Emerging Oral Opportunistic PathogenJ Dent Res 86(3):204-215, 2007

363. Fidel PL Jr, Vazquez JA, Sobel JD (1999). Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12:80-96.

364. Krcmery K Jr (1999). Torulopsis glabrata—an emerging yeast pathogen in cancer patients. Int J Antimicrob Agents 11:1-6.

365. Arendrup M, Horn T, Frimodt-Moller N (2002). In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30:286-291.

366. Biasoli MS, Tosello ME, Magaro HM (2002). Adherence of Candida strains isolated from the human gastrointestinal tract. Mycoses 45:465-459.

367. Luo G, Samaranayake LP (2002). Candida glabrata, an emerging fungal pathogen, exhibits superior relative cell surface hydrophobicity and adhesion to denture acrylic surfaces compared with Candida albicans. APMIS 110:601-610.

368. Kaur R, Domergue R, Zupancic ML, Cormack BP (2005). A yeast by any other name: Candida glabrata and its interaction with the host. Curr Opin Microbiol 8:378-384.

369. Chakrabarti A, Nayak N, Talwar P (1991). In vitro proteinase production by Candida species. Mycopathologia 114:163-168.

370. Samaranayake YH, MacFarlane TW, Samaranayake LP, Aitchison T (1994). The in vitro proteolytic and saccharolytic activity of Candida species cultured in human saliva. Oral Microbiol Immunol 9:229-235.

371. Brockert PJ, Lachke SA, Srikantha T, Pujol C, Galask R, Soll DR (2003). Phenotypic switching and mating type switching of Candida glabrata at sites of colonization. Infect Immun 71:7109-7118.

372. Lachke SA, Joly S, Daniels K, Soll DR (2002). Phenotypic switching and filamentation in Candida glabrata. Microbiology 148:2661-2674.

373. Helmerhorst EJ, Venuleo C, Beri A, Oppenheim FG (2005). Candida glabrata is unusual with respect to its resistance to cationic antifungal proteins. Yeast 22:705-714.

374. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J (1999). The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 43:2753-2765.

375.  Chandra, J., Mukherjee, P.K., Leidich, S.D., Faddoul, F.F., Hoyer, L.L., Douglas, L.J., Ghannoum, M.A., 2001a. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J. Dent. Res. 80, 903–908.

376. Chandra, J., Kuhn, D.M., Mukherjee, P.K., Hoyer, L.L., McCormick, T., Ghannoum, M.A., 2001b. Biofilm formation by the fungal pathogen Candida albicans—development, architecture and drug resistance. J. Bacteriol. 183, 5385–5394.

377. Samaranayake LP (1991). Superficial oral fungal infections. CurrOpin Dent 1:415-422.

378. Axell T, Samaranayake LP, Reichart PA, Olsen(1997).

A proposal for reclassification of oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:111-1 12.

379. Katou F, Ohtani H, Nakayama T, Ono K, Matsushima K, Saaristo A, et al. (2001). Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am J Pathol 158:1263-1270.

380. Krisanaprakornkit S, Jotikasthira D, Dale BA (2003). Intracellular calcium in signaling human beta-defensin-2 expression in oral epithelial cells. J Dent Res 82:877-882.

381. Steele C, Leigh J, Swoboda R, Ozenci H, Fidel PL Jr (2001). Potential role for a carbohydrate moiety in anti-Candida activity of human oral epithelial cells. Infect Immun 69:7091-7099.

382. Nomanbhoy F, Steele C, Yano J, Fidel PL Jr (2002). Vaginal and oral epithelial cell anti-Candida activity. Infect Immun 70:7081-7088.

383. Yano J, Lilly E, Steele C, Fortenberry D, Fidel PL (2005). Oral and vaginal epithelial cell anti-Candida activity is acid-labile and does not require live epithelial cells. Oral Microbiol Immunol 20:199-205.

384. Csato M, Kenderessy AS, Judak R, Dobozy A (1990). Inflammatory mediators are involved in the Candida albicans killing activity of human epidermal cells. Arch Dermatol Res 282:348-350.

385. Brandtzaeg P, Gabrielsen TO, Dale I, Muller F, Steinbakk M, Fagerhol MK (1995). The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Biol 371(A):201- 206.

386. Dale BA, Kimball JR, Krisanaprakornkit S, Roberts F, Robinovitch M, O'Neal R, et al. (2001). Localized antimicrobial peptide expression in human gingiva. J Periodontal Res 36:285-294.

387. Goodrum KJ, Poulson-Dunlap J (2002). Cytokine responses to group B streptococci induce nitric oxide production in respiratory epithelial cells. Infect Immun 70:49-54.

388. Dongari-Bagtzoglou A, Villar CC, Kashleva H. Candida albicans-infected oral epithelial cells augment the anti-fungal activity of human neutrophils in vitro. Med Mycol. 2005 Sep;43(6):545-9.

389. Ashman RB, Papadimitriou JM (1995). Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev 59:646-672.

390. Parkos CA (1997). Cell adhesion and migration. I. Neutrophil adhesive interactions with intestinal epithelium. Am J Physiol 273:G763-G768.

391. Liu Y, Buhring HJ, Zen K, Burst SL, Schnell FJ, Williams IR, et al. (2002). Signal regulatory protein (SIRPalpha), a cellular ligand for CD47, regulates neutrophil transmigration. J Biol Chem 277:10028- 10036.

392. Goodrum KJ, Poulson-Dunlap J (2002). Cytokine responses to group B streptococci induce nitric oxide production in respiratory epithelial cells. Infect Immun 70:49-54.

393. Tosi MF, Hamedani A, Brosovich J, Alpert SE (1994). ICAM-1-independent, CD18-dependent adhesion between neutrophils and human airway epithelial cells exposed in vitro to ozone. J Immunol 152:1935-1942.

394. Challacombe SJ (1994). Immunologic aspects of oral candidiasis. Oral Surg Oral Med Oral Pathol 78:202-210.

395. Eversole LR, Reichart PA, Ficarra G, Schmidt-Westhausen A, Romagnoli P, Pimpinelli N (1997). Oral keratinocyte immune responses in HIVassociated candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:372-380.

396. Epstein JB, Hancock PJ, Nantel S (2003). Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96:154-163.

397. Myoken Y, Sugata T, Fujita Y, Kohara T, Mikami Y (2004). Oropharyngeal Candida colonization and infection in neutropenic patients with hematologic malignancies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:137-138; author reply 138.

398. Dongari-Bagtzoglou A, Fidel PL Jr. The host cytokine responses and protective immunity in oropharyngeal candidiasis. J Dent Res 2005: 84: 966–977.

399. Ueta E, Osaki T, Yoneda K, Yamamoto T (1993). Functions of salivary polymorphonuclear leukocytes (SPMNs) and peripheral blood polymorphonuclear leukocytes (PPMNs) from healthy individuals and oral cancer patients. Clin Immunol Immunopathol 66:272-278.

400. Tanida T, Ueta E, Tobiume A, Hamada T, Rao F, Osaki T (2001). Influence of aging on candidal growth and adhesion regulatory agents in saliva. J Oral Pathol Med 30:328-335.

401. Ueta E, Tanida T, Doi S, Osaki T (2000). Regulation of Candida albicans growth and adhesion by saliva. J Lab Clin Med 136:66-73.

402. Lehrer RI, Cline MJ (1969). Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 48:1478-1488.

403. Schaller M, Boeld U, Oberbauer S, Hamm G, Hube B, Korting HC (2004). Polymorphonuclear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an in vitro model of oral candidosis. Microbiology 150:2807-2813.

404. Nielsen H, Kharazmi A, Faber V (1986). Blood monocyte and neutrophil functions in the Acquired Immune Deficiency Syndrome. Scand J Immunol 24:291-296.

405. Ellis M, Gupta S, Galant S, Hakim S, VandenVen C, Toy C, et al. (1988). Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 158:1268-1275.

406. Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M (1990). Impairment of neutrophil chemotactic and bactericidal function in children infected with HIV type 1 and partial reversal after in vitro exposure to GM-CSF. J Pediatrics 117:531-540.

407. Murphy PM, Lane CH, Fauci AS, Gallin JI (1988). Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis 158:627-631.

408. Pitrak DL, Bak PM, DeMarais P, Novak RM, Andersen BR (1993). Depressed neutrophil superoxide production in HIV infection. J Infect Dis 167:1406-1410.

409. Brettle RP (1997). Bacterial infections in HIV: the extent and nature of the problem. Int J STD AIDS 8:5-15.

410. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH (1998). Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 102:663-670.

411. Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M (1990). Impairment of neutrophil chemotactic and bactericidal function in children infected with HIV type 1 and partial reversal after in vitro exposure to GM-CSF. J Pediatrics 117:531-540.

412. Meyer CN, Nielsen H (1996). Priming of neutrophil and monocyte activation in HIV infection. APMIS 104:640-646.

413. Fidel PL Jr (2004). History and new insights into host defense against vaginal candidiasis. Trends Microbiol 12:220-227.

414. Fidel PL Jr (2002a). Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 40:359-375.

415. Fidel PL Jr (2002b). The protective immune response against vaginal candidiasis: lessons learned from clinical studies and animal models. Int Rev Immunol 21:515-548.

416. Leigh JE, Barousse M, Swoboda RK, Myers T, Hager S, Wolf NA, et al. (2001). Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis 183:277-285.

417. Kunkl A, Mortara L, Valle MT, Fenoglio D, Terranova MP, Megiovanni AM, et al. (1998). Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virusinfected persons. J Infect Dis 178:488-496.

418. Deslauriers N, Cote L, Montplaisir S, de Repentigny L (1997). Oral carriage of Candida albicans in murine AIDS. Infect Immun 65:661- 667.

419. Farah CS, Elahi S, Pang G, Gotjamanos T, Seymour GJ, Clancy RL, et al. (2001). T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis. Infect Immun 69:6110- 6118.

420. Farah CS, Elahi S, Drysdale K, Pang G, Gotjamanos T, Seymour GJ, et al. (2002a). Primary role for CD4(+) T lymphocytes in recovery from oropharyngeal candidiasis. Infect Immun 70:724-731.

421. Elahi S, Pang G, Clancy R, Ashman RB (2000). Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis. Infect Immun 68:5771-5777.

422. Ashman RB, Papadimitriou JM (1995). Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev 59:646-672.

423. Zunino SJ, Hudig D (1988). Interactions between human natural killer (NK) lymphocytes and yeast cells: human NK cells do not kill Candida albicans, although C. albicans blocks NK lysis of K562 cells. Infect Immun 56:564-569.

424. Balish E, Warner T, Pierson CJ, Bock DM, Wagner RD (2001). Oroesophageal candidiasis is lethal for transgenic mice with combined natural killer and T-cell defects. Med Mycol 39:261-268.

425. Wozniak KL, Leigh JE, Hager S, Swoboda RK, Fidel PL Jr (2002). A comprehensive study of Candida-specific antibodies in the saliva of human immunodeficiency virus-positive individuals with oropharyngeal candidiasis. J Infect Dis 185:1269-1276.

426. Drobacheff C, Millon L, Monod M, Piarroux R, Robinet E, Laurent R, et al. (2001). Increased serum and salivary immunoglobulins against Candida albicans in HIV-infected patients with oral candidiasis. Clin Chem Lab Med 39:519-526.

427. Shoham S, Levitz SM. The immune response to fungal infections Br J Haematol. 2005 Jun;129(5):569-82

428. Diamond, R.D., Clark, R.A. & Haudenschild, C.C. (1980) Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. Journal of Clinical Investigation, 66, 908–917.

429. Bellocchio, S., Montagnoli, C., Bozza, S., Gaziano, R., Rossi, G., Mambula, S.S., Vecchi, A., Mantovani, A., Levitz, S.M. & Romani, L. (2004) The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. Journal of Immunology, 172, 3059–3069.

430. Romani, L. (2004) Immunity to fungal infections. Natural Review of Immunology, 4, 1–23.

431. Clemons KV, Stevens DA (2001). Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin Respir  Infect 16:60-66.

432. d’Ostiani, C.F., Del Sero, G., Bacci, A., Montagnoli, C., Spreca, A., Mencacci, A., Ricciardi-Castagnoli, P. & Romani, L. (2000) Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. Journal of Experimental Medicine, 191, 1661–1674.

433. Marcus J, Grossman ME, Yunakov MJ, Rappaport F. Disseminated candidiasis, Candida arthritis, and unilateral skin lesions. J Am Acad Dermatol. 1992 Feb;26(2 Pt 2):295-7.

434. Osthoff M, Hilge R, Schulze-Döbold C, Bogner JR. Endogenous endophthalmitis with azole-resistant Candida albicans--Case report and review of the literature. Infection. 2006 Oct;34(5):285-8.

435. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000 Oct;13(4):662-85

436. Ellis ME, Al-Abdely H, Sandridge A, Greer W, entura W. Fungal endocarditis: evidence in World iterature, 1965±1995. CID 2001; 32: 50±62.

437. Gilleece A, Fenelon L. Nosocomial infective endocarditis.  Hosp Inf 2000; 46: 83±88.

438. Guze L, Pearce M. Hospital-acquired bacterial endocarditis. Arch Intern Med 1963; 112: 56±62.

439. Rubinstein E, Lang R. Fungal endocarditis. Eur Heart J 1995; 16 (Suppl. B): S84±S89.

440. Callen PW, Filly RA, Marcus FS. Ultrasonography and computerised tomography in the evaluation of hepatic micro abscesses in the immunosuppressed patient. Radiology 1980;136:433– 434.

441. Linker CA, De Gregoria MW, Reis CA. Computerised tomography in the diagnosis of systemic candidiasis in patients with acute leukemia. Med Pediatr Oncol 1984;12:380 –5.

442. Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P. Hepatosplenic candidiasis in patients with acute leukemia, incidence and prognostic implications. Clin Infect Dis 1997;24:375–80.. Colović M, Lazarević V, Colović R, Janković G, Suvajdzić N, Bogdanović A, Bila J. Hepatosplenic candidiasis after neutropenic phase of acute leukaemia. Med Oncol. 1999 Jul;16(2):139-42

443. Grois N, Mostbeck G, Scherrer R, Chatt A, Schwarzinger I, Muhm M, et al. Hepatic and splenic abscesses, a common complication of intensive chemotherapy for acute myeloid leukemia. Ann Hematol 1991;63:33–8.

444. Murillo LA, Newport G, Lan CY, Habelitz S, Dungan J, Agabian NM:Genome-wide transcription profiling of the early phase ofbiofilm formation by Candida albicans. Eukaryot Cell 2005,4:1562-1573.

445. Garcia-Sanchez S, Aubert S, Iraqui I, Janbon G, Ghigo JM, d’Enfert C: Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot Cell 2004, 3:536-545.

446. Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr Opin Microbiol. 2006 Dec;9(6):588-94. Epub 2006 Oct 20.

447. Baillie GS, Douglas LJ: Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 1999, 48:671-679.

448. Hawser SP, Baillie GS, Douglas LJ: Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol 1998, 47:253-256.

449. Baillie GS, Douglas LJ: Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000, 46:397-403.

450. Al-Fattani MA, Douglas LJ: Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol 2006, 55:999-1008.

451. Keller L, Surette MG: Communication in bacteria: an ecological and evolutionary perspective. Nat Rev Microbiol 2006, 4:249-258.

452. Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, Dussault P, Nickerson KW: Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001, 67:2982-2992.

453. Greenberg EP: Bacterial communication and group behavior. J Clin Invest 2003, 112:1288-1290.

454. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002 Apr;15(2):167-93.

455. Lawrence, J. R., D. R. Korber, B. D. Hoyle, and J. W. Costerton. 1991. Optical sectioning of microbial biofilms. J. Bacteriol. 173:6558-6567

456. Munk PL, Lee MJ, Poon PY, O’Connell JX, Coupland DB, Janzen DL, Logan PM, Dvorak MF. Candida osteomyelitis of the lumbar spine. Skeletal Radiol 1997;26:42—6.

457. Arias F, Mata-Essayag S, Landaeta ME, Capriles CH, Perez C, Nunez MJ, Carvajal A, Silva M. Candida albicans osteomyelitis: case report and literature review. Int J Infect Dis. 2004 Sep;8(5):307-14. Review.

458. Torres-Ramos FM, Botwin K, Shah CP. Candida spondylodiscitis: an unusual case of thoracolumbar pain with review of imaging findings and description of the clinical condition. Pain Physician. 2004 Apr;7(2):257-60.

459. Rodriguez D, Almirante B, Park BJ, Cuenca-Estrella M, Planes AM, Sanchez F, Gene A, Xercavins M, Fontanals D, Rodriguez-Tudela JL, Warnock DW, Pahissa A; Barcelona Candidemia Project Study Group. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J. 2006 Mar;25(3):224-9.

460. Casado, J. L., Quereda, C., Oliva, J., Navas, E., Moreno, A., Pintado, V., Cobo, J., & Corral, I. (1997). Candidal meningitis in HIV-infected patients: analysis of 14 cases. Clin Infect Dis, 25, 673–676.

461. Nguyen, M. H. & Yu, V. L. (1995). Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis, 21, 323–327.

462. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000 Jul;37(3):169-79. Review.  PMID: 10904190 [PubMed - indexed for MEDLINE]

463. El-Ebiary M, Torres A, Fabrega N, de la Bellacasa JP, Gonzalez J, Ramirez J, et al. Significance of the isolation of

Candida species from respiratory samples in critically ill, non-neutropenic patients. Am J Respir Crit Care Med. 1997;156:583–90.

464. Rodriguez LJ, Anaissie EJ, Rex JH. Candida. In: Sarosi GA, Davies SF, editors. Fungal disease of the lung. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:115–22.

465. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients

with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991; 325:1274–7.

466. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23:317–22.

467. Pagano L, Caira M, Fianchi L. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. Ann Med. 2005;37(4):259-69. Review.

468. Samson J. Candidoses buccales: épidémiologie, diagnostic et traitement. Rev Mens Suisse Odontostomatol 1999,100: 548-559 .

469. Farah CS, Ashman RB, Challacombe SJ. Oral candidosis. Clin Dermatol. 2000 Sep-Oct;18(5):553-62

470. Sharma G, Pai KM, Suhas S, Ramapuram JT, Doshi D, Anup N. Oral manifestations in HIV/AIDS infected patients from India. Oral Dis. 2006 Nov;12(6):537-42.

471. Palmer GD, Robinson PG, Challacombe SJ, et al. Aetio- 560 FARAH ET AL. Clinics in Dermatology Y 2000;18:553–562 logical factors for oral manifestations of HIV. Oral Dis 1996;2:193–7.

472. Agbo-Godeau S, Guedj A. Mycoses buccales. 2005. EMC 22-045-M-10

473. Finlay IG. Oral symptoms and Candida in the terminally ill. Br Med J 1986;292:592–3.

474. Kostiala I, Kostiala AAI, Kahanpaa A. Acute fungal stomatitis in patients with haematologic malignancies: Quantity and species of fungi. J Infect Dis 1982;146:101.

475. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989;18:554–64.

476. Samson J, Carrel J.-P., Pessotto S. Les candidoses buccales, Rev Med Suisse Rom 1998, 118, 51-56.

477. Terai H, Shimahara M. Partial atrophic tongue other than median rhomboid glossitis. Clin Exp Dermatol. 2007 Jul;32(4):381-4. Epub 2007 Apr 18.

478. Terai H, Shimahara M. Atrophic tongue associated with Candida. J Oral Pathol Med. 2005 Aug;34(7):397-400.

479. Lago-Mendez L, Blanco-Carrion A, Diniz-Freitas M, Gandara-Vila P, Garcia-Garcia A, Gandara-Rey JM. Rhomboid glossitis in atypical location: case report and differential diagnosis. Med Oral Patol Oral Cir Bucal. 2005 Mar-Apr;10(2):123-7

480. Terai H, Shimahara M. Tongue pain: burning mouth syndrome vs Candida- associated lesion. Oral Dis. 2007 Jul;13(4):440-2.

481. Osaki T, Yoneda K, Yamamoto T, Ueta E, Kimura T. Candidiasis may induce glossodynia without objective manifestation.Am J Med Sci. 2000 Feb;319(2):100-5.

482. Brown RS, Krakow AM. Median rhomboid glossitis and a "kissing" lesion of the palate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Nov;82(5):472-3.

483. Touyz LZ, Peters E. Candidal infection of the tongue with nonspecific inflammation of the palate. Oral Surg Oral Med Oral Pathol. 1987 Mar;63(3):304-8.

484. Budtz-Jorgensen E. The significance of Candida albicans in denture stomatitis. Scand J Dent Res. 1974;82(2):151-90.

485. Samaranayake LP. Superficial oral fungal infections. Curr Opin Dent. 1991 Aug;1(4):415-22.

486. Krogh P, Hald B, Holmstrup P (1987a). Possible mycologic aetiology of oral mucosal cancer: catalytic potential of infecting Candida albicans and other yeasts in production of Nnitrosobenzylmethylamine. Carcinogenesis 8:1543-1548.

487. Krogh P, Holmstrup P, Thorn JJ, Vedtofte P, Pindborg JJ (1987b). Yeast species and biotypes associated with oral leukoplakia and lichen planus. Oral Surg Oral Med Oral Pathol 63:48-54.

488. Newton AV, 1962, Denture sore mouth: a possiblre aetiology. Br. Dent J, 112:357-360

489. Budtz-Jorgensen E. Candida-associated denture stomatitis and angular cheilitis. In: Samaranayake LP, MacFarlane TW, editors, Oral candidosis. London: Wright, 1990.

490. Farah CS, Ashman RB, Challacombe SJ. Oral candidosis. Clin Dermatol. 2000 Sep-Oct;18(5):553-62.

491. Budtz-JorgensenE, ., The significanceo f Candida albicans in denture stomatitis. Scandinavian Journal of Dental Research, 1974, 82, 151-190.

492. Iacopino, A. M. and Wathen, W. F., Oral candidalinfection and denture stomatitis: a comprehensivere view, Journal of the America Dental Association, 1992, 123, 46-51

492. Arendorf TM, Walker DM. Denture stomatitis: a review. J Oral Rehabil 1987;14:217-27.

493. Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul;98(1):53-9.

494. Williams DM (1969). Chronic hyperplastic candidiasis and squamous carcinoma. Br J Dermatol 81:125-127.

495. McCullough M, Jaber M, Barrett AW, Bain L, Speight P, Porter SR (2002). Oral yeast carriage correlates with presence of oral epithelial dysplasia. Oral Oncol 38:391-393.

496. Samaranayake LP, MacFarlane TW, editors (1990). Oral candidosis. London: Butterworth.

497. Lacey CJ, Dutton S, Smith RA, Walmsley RM, Wilkinson BM, Evans EG, et al. (1995). The oncogenic potential of Candida in the female genital tract. Int J Gynecol Cancer 5:8-14

498. Dupperat B Puissant A, Kuffer R, Badillet G, Lamberton JN, Serny J, (1977)Deux cas de candidose chronique avec macroglossite et macrocheilite sclérosante. Ann Dermatol Venerol, 104: 761-764

499. Reichart PA, Weigel D, Schmidt-Westhausen A, Pohle H-D (1997). Exfoliative cheilitis (EC) in AIDS: association with Candida infection. J Oral Pathol Med 26: 290 293.

500. Reade PC, Rich Am, Hay KD, Radden BG. Cheilo-candidosis − a possible clinical entity. Report of 5 cases. Br Dent J 1982; 152(9):305-8

501. Terai H, Shimahara M. Cheilitis as a variation of Candida-associated lesions. Oral Dis. 2006 May;12(3):349-52.

502. Hatchuel DA, Peters E, Lemmer J, Hille JJ, McGaw WT. Candidal infection in oral lichen planus. Oral Surg Oral Med Oral Pathol. 1990 Aug;70(2):172-5.

503. Lundstrom IM, Anneroth GB, Holmberg K. Candida in patients with oral lichen planus. Int J Oral Surg. 1984 Jun;13(3):226-38.

504. van der Waal RI, Schulten EA, van de Scheur MR, Wauters IM, Starink TM, van der Waal I. Cheilitis granulomatosa. J Eur Acad Dermatol Venereol. 2001 Nov;15(6):519-23. Review.

505. Brook IM, King DJ, Miller ID. Chronic granulomatous cheilitis and its relationship to Crohn’s disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1983: 56: 405-408.

506. Misra S, Ament ME. Orofacial lesions in Crohn’s disease. Am J Gastroenterol 1996: 91: 1651-1653.

507. Ridder GJ, Fradis M, Lohle E. Cheilitis granulomatosa Miescher: treatment with clofazimine and review of the literature. Ann Otol Rhinol Laryngol. 2001 Oct;110(10):964-7.

508. Alkan A, Metin M. Maxillary double lip: report of two cases. J Oral Sci. 2001 Mar;43(1):69-72

509. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol. 2005 May-Jun;8(3):287-304

510. Padgham ND, Bingham BJ, Purdue BN. Episodic macroglossia in Down's syndrome. J Laryngol Otol. 1990 Jun;104(6):494-6.

511. Emmanouil-Nikoloussi EN, Kerameos-Foroglou C. Developmental malformations of human tongue and associated syndromes (review). Bull Group Int Rech Sci Stomatol Odontol. 1992 Mar-Jun;35(1-2):5-12.

512. Vogel JE, Mulliken JB, Kaban LB. Macroglossia: a review of the condition and a new classification. Plast Reconstr Surg. 1986 Dec;78(6):715-23.

513. Cawson RA (1966a). Chronic oral candidiasis and leukoplakia. Oral Surg Oral Med Oral Pathol 22:582-591.

514. Cawson RA, Lehner T (1968). Chronic hyperplastic candidosis-candidal leukoplakia. Br J Dermatol 80:9-16.

515. Pindborg JJ, Reibel J, Roed-Petersen B, Mehta FS (1980). Tobaccoinducedchanges in oral leukoplakic epithelium. Cancer 45:2330-2336.

516. Williams DW, Potts AJ, Wilson MJ, Matthews JB, Lewis MA (1997). Characterisation of the inflammatory cell infiltrate in chronic hyperplastic candidosis of the oral mucosa. J Dent Res 75:1144.

517. Sitheeque MA, Samaranayake LP. Chronic hyperplastic candidosis/candidiasis (candidal leukoplakia). Crit Rev Oral Biol Med. 2003;14(4):253-67.

518. Williams DW, Jones HS, Allison RT, Potts AJ, Lewis MA (1998). Immunocytochemical detection of Candida albicans in formalin fixed, paraffin embedded material. J Clin Pathol 51:857-859.

519. Merz WG, Sandford G, Evans GLClinical evaluation of the addition of gentamicin to commercially prepared mycological media. J Clin Microbiol. 1976 May;3(5):496-500

520. Stedham MA, Kelley DC, Coles EH. Modified Pagano Levin medium to isolate Candida species. Appl Microbiol. 1966 Jul;14(4):525-8.

521. Salkin IF. New medium for differentiation of Candida albicans from Candida stellatoidea. J Clin Microbiol. 1979 Apr;9(4):551-3.

522. Elena Eraso, María D. Moragues, María Villar-Vidal, Ismail H. Sahand, Nagore González-Gómez, José Pontón, and Guillermo Quindós Evaluation of the New Chromogenic Medium Candida ID 2 for Isolation and Identification of Candida albicans and Other Medically Important Candida Species Clin Microbiol. 2006 September; 44(9): 3340–3345.

523. Sullivan D. J., D.C. Coleman et al. Candida dubliniensis: An update 1999. Rev. Iberoam Micol.,16 : 72-76.

524 Koehler AP, Chu KC, Houang ET, Cheng AF. Simple, Reliable, and Cost-Effective Yeast Identification

Scheme for the Clinical Laboratory 1999. J Clin Microbiol. 1999 Feb;37(2):422-6.

525. Willinger B., Manafi M. Evaluation of CHROMagar Candida for rapid screening of clinical specimens for Candida species. 1999. Mycoses, 42 : 61-65.

526. Martin MV, Schneidau JD Jr. A simple and reliable assimilation test for the identification of candida species. Am J Clin Pathol. 1970 Jun;53(6):875-9

527. Taschdjian CL, Burchall JJ, Kozinn PJ. Rapid identification of Candida albicans by filamentation on serum and serum substitutes. AMA J Dis Child. 1960 Feb;99:212-5

528. Staib P, Morschhä J. Chlamydospore formation on Staib agar as a species- specific characteristic on Candida dubliniensis. Mycoses 1999; 42: 521–4.

529. Mosaid AA, Sullivan DJ, Coleman DC. Differentiation of Candida dubliniensis from Candida albicans on Pal’s Agar. J Clin Microbiol 2003; 41: 4787–9.

530. Mosca CO, Moragues MD, Llovo J, Mosaid AA, Coleman DC, Ponto´n J. Casein agar: a useful medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol 2003; 41: 1259–62.

531. Khan ZU, Ahmad S, Mokaddas E, Chandy R. Tobacco agar, a new medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol 2004; 42: 4796–8.

532. Grillot, R. 1996. Les mycoses humaines: de´marche diagnostique. Elsevier, Paris, France.

533. Fenn, J. P., H. Segal, L. Blevins, S. Fawson, P. Newcomb-Gayman, and K. C. Carroll. 1996. Comparison of the Murex Candida albicans CA 50 test with germ tube production for identification of C. albicans. Diagn. Microbiol. Infect. Dis. 24:31–35.

534. Brawner, D. L., and J. E. Cutler. 1984. Variability in expression of a cell surface determinant on Candida albicans evidenced by an agglutinating monoclonal antibody. Infect. Immun. 43:966–972.

535. Hopwood, V., D. Poulain, B. Fortier, G. Evans, and A. Vernes. 1986. A monoclonal antibody to a cell wall component of Candida albicans. Infect. Immun. 54:222–227.

536. Miyakawa, Y., K. Kagaya, Y. Fukazawa, and G. Soe. 1986. Production and characterization of agglutinating monoclonal antibodies against predominant antigenic factors of Candida albicans. J. Clin. Microbiol. 23:881–886.

537. Polonelli, L., and G. Morace. 1986. Specific and common antigenic determinants of Candida albicans isolates detected by monoclonal antibody. J. Clin. Microbiol. 23:366–368.

538. Shinoda, T., L. Kaufman, and A. A. Padhye. 1981. Comparative evaluation of the Iatron serological Candida check kit and the API 20C kit for the identification of medically important Candida species. J. Clin. Microbiol. 13:513– 518.

539. Taguchi, M., M. Tsukiji, and T. Tsuchiya. 1979. Rapid identification of yeasts by serological methods. A combined serological and biological method. Sabouraudia 17:185–191.

540. Freydiere, A. M., L. Buchaille, R. Guinet, and Y. Gille. 1997. Evaluation of latex reagents for rapid identification of Candida albicans and C. krusei colonies. J. Clin. Microbiol. 35:877–880.

541. Marot-Leblond A, Grimaud L, David S, Sullivan DJ, Coleman DC, Ponton J, Robert R. Evaluation of a rapid immunochromatographic assay for identification of Candida albicans and Candida dubliniensis. J Clin Microbiol. 2004 Nov;42(11):4956-60.

542. Crist AE Jr, Dietz TJ, Kampschroer K. Comparison of the MUREX C. albicans, Albicans-Sure, and BactiCard Candida test kits with the germ tube test for presumptive identification of Candida albicans. J Clin Microbiol. 1996 Oct;34(10):2616-8

543. Pagano, J., J. D. Levin, and W. Trejo. 1958. Diagnostic medium for differentiation of species of Candida. Antibiotics Annu. 1957-1958:137-143.

544. Denny MJ, Partridge BM. Tetrazolium medium as an aid in the routine diagnosis in Candida. J Clin Pathol. 1968 May;21(3):383-6.

545. Freydiere AM, Buchaille L, Guinet R, Gille Y. Evaluation of latex reagents for rapid identification of Candida albicans and C. krusei colonies. J Clin Microbiol. 1997 Apr;35(4):877-80

546. Marot-Leblond A, Beucher B, David S, Nail-Billaud S, Robert R. Development and evaluation of a rapid latex agglutination test using a monoclonal antibody to identify Candida dubliniensis colonies. J Clin Microbiol. 2006 Jan;44(1):138-42

547. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E; Global Antifungal Surveillance StudyResults from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007 Jun;45(6):1735-45. Epub 2007 Apr 18

548. Willinger B, Wein S, Hirschl AM, Rotter ML, Manafi M. Comparison of a new commercial test, GLABRATA RTT, with a dipstick test for rapid identification of Candida glabrata. J Clin Microbiol. 2005 Jan;43(1):499-501.

549. Freydiere AM, Perry JD, Faure O, Willinger B, Tortorano AM, Nicholson A, Peman J, Verweij PE. Routine use of a commercial test, GLABRATA RTT, for rapid identification of Candida glabrata in six laboratories. J Clin Microbiol. 2004 Oct;42(10):4870-2.

550. Freydiere AM, Robert R, Ploton C, Marot-Leblond A, Monerau F, Vandenesch F. Rapid identification of Candida glabrata with a new commercial test, GLABRATA RTT. J Clin Microbiol. 2003 Aug;41(8):3861-3.

551. Liguori G, Lucariello A, Colella G, De Luca A, Marinelli P. Microbiological and immunological features of oral candidiasis. Microbiol Immunol. 2007;51(8):713-9.

552. Trousseau U. Lectures on clinical medicine delivered at the Hotel-Dieu Paris. London: New Sydenham Society, 1869.

553. Klein, R.S., Harris, C.A., Small, C.B., Moll, B., Lesser, M. & Friedland, G.H. (1984) Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. New England Journal of Medicine, 311, 354–358.

554. Guggenheimer, J., Moore, P.A., Rossie, K., Myers, D., Mongelluzzo, M.B., Block, H.M., Weyant, R. & Orchard, T. (2000) Insulin-dependent diabetes mellitus and oral soft tissue pathologies: II. Prevalence and characteristics of Candida and Candidal lesions. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 89, 570–576.

555. Hughes WT. Candidiasis. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 3rd ed. Philadelphia: Saunders, 1992:1907-16.

556. Kozinn PJ, Taschdjian CL, Wiener H, Dragutsky D, Minsky A. Neonatal candidiasis. Pediatr Clin North Am 1960;5:803-15.

557. Jennison RF. Thrush in infancy. Arch Dis Child 1977;52:747-9.

558. Hoppe JE.Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal. Pediatr Infect Dis J. 1997 Sep;16(9):885-94.

559. Fitzpatrick RE, Newcomer VD. Candidiasis. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 3rd ed. Philadelphia: Saunders, 1992:805-16.

560. Schwarze R, Blaschke-Hellmessen R, Hinkel GK, Hoffmann H, Weigl I. Untersuchungen zur Soorprophylaxe Neugeborener. Kinderarztl Prax 1976;44:305-14.

561. Zimmerman LE (1955). Fatal fungus infections complicating other diseases. Am J Clin Pathol 25:46-65.

562. S.R. Lockhart, S. Joly, K. Vargas, J. Swails-Wenger, L. Enger, D.R. SollNatural Defenses against Candida Colonization Breakdown in the Oral Cavities of the ElderlyJ Dent Res 78(4): 857-868, April, 1999

563. Burns EA, Goodwin JS. Immunodeficiency of aging. Drugs Aging 1997;11(5): 374-97.

564. LeMaoult J, Szabo P, Weksler ME. Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunol Rev 1997;160:115-26.

565. Mountz JD, Wu J, Zhou T, Hsu HC. Cell death and longevity: implications of Fasmediated apoptosis in T-cell senescence. Immunol Rev 1997;160:19-30.

566. Song H, Price PW, Cerny J. Age-related changes in antibody repertoire: contribution from T cells. Immunol Rev 1997;160:55-62.

567. Primary immunodeficiency diseases. Report of a WHO Scientific Group. Clin Exp Immunol. 1995 Jan;99 Suppl 1:1-24. Review. No abstract available.

568. Porter SR, Scully C. Orofacial manifestations in the primary immunodeficiency disorders. Oral Surg Oral Med Oral Pathol 1994;78(1):4-13.

569. Elhasid R, Etzioni A. Major histocompatibility complex class II deficiency: a clinical review. Blood Rev 1996;10(4):242-8.

570. Kirkpatrick CH. Host factors in defense against fungal infections. Am J Med. 1984 Oct 30;77(4D):1-12.

571. Samson J, Carrel JP, Lombardi T, Candidoses buccales et infection à VIH, Med Buccales Chir Buccale 1998, 4 :137-150

572. Ship JA, Vissink A, Challacombe SJ. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S6.e1-14

573. Ship JA, Hu K. Radiotherapy-induced salivary dysfunction. Semin Oncol 2004;31(6 Suppl 18):29-36.

574. Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14(3):213-25

575. Jensen SB, Pedersen AM, Reibel J, Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 2003;11(4):207-25.

576. Amerongen AV, Veerman EC. Saliva—the defender of the oral cavity. Oral Dis 2002;8(1):12-22.

577. Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, et al. Oral Candida isolates in patients

undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 2004;19(6):347-51

578. Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer 2003;88(7):1012-6.

579. Reichart PA. Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi’s sarcoma. Med Microbiol Immunol (Berl) 2003;192(3):165-9.

580. de Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 2004;17(4):729-59, table of contents.

581. Costeas PA, Koumouli A, Giantsiou-Kyriakou A, et al. Th2/Th3 cytokine genotypes are associated with pregnancy loss. Human Immunology 2004; 65:135–41.

582. Gaunt G, Ramin K. Immunological tolerance of the human fetus. Am J Perinatol 2001; 18:299–312.

583. Poole J, Claman HN. Immunology of pregnancy: implications for the mother. Clin Rev Allergy Immunol 2004; 26:161–70.

584. Krasnow J, Tollerud D, Naus G, et al. Endometrial Th2 cytokine expression throughout menstrual cycle and early pregnancy. Human Reproduction 1996; 11:1747–54.

585. Elenkov I, Wilder R, Bakalov V, et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 2001; 86:4933–8.

586. Koguchi Y, Kawakami K. Cryptococcal infection and Th1-Th2 cytokine balance. Int Rev Immunol 2002; 21:423–38.

587.Singh N, Perfect JR, Immune Reconstitution Syndrome and Exacerbation of Infections after Pregnancy, Clin Infect Dis. 2007 Nov 1;45(9):1192-9.

588. Sarifakioglu E, Gunduz C, Gorpelioglu C. Oral mucosa manifestations in 100 pregnant versus non-pregnant patients: an epidemiological observational study. Eur J Dermatol. 2006 Nov-Dec;16(6):674-6.

589. Walsh H, Hildebrandt RJ, Prystowsky H. Candidial vaginitis associated with the use of oral progestational agents. Am J Obstet Gynecol. 1965 Nov 15;93(6):904-5.

590. Morris CA. The influence of oral contraceptives on the presence and persistence of Candida albicans and beta-haemolytic Streptococci in the vagina. J Clin Pathol. 1968 Nov;21(6):791

591. Cetin M, Ocak S, Gungoren A, Hakverdi AU. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis. 2007;39(6-7):584-8.

592. Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, Blasi N, Festa A. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol. 2003 Sep 10;110(1):66-72.

593. Kim A. Brogden and Janet M. Guthmiller,Polymicrobial Diseases, ASM Press, 2002,

593. Darwazeh AM, Lamey PJ, Samaranayake LP, MacFarlane TW, Fisher BM, Macrury SM et al. The relationship between colonisation, secretor status and in-vitro adhesion of Candida albicans to buccal epithelial cells from diabetics. J Med Microbiol 1990; 33: 43–49.

594. Willis AM, Coulter WA, Sullivan DJ, Coleman DC, Hayes JR, Bell PM et al. Isolation of C. dubliniensis from insulin-using diabetes mellitus patients. J Oral Pathol Med 2000; 29: 86–90.

595. Hill LV, Tan MH, Pereira LH, Embil JA. Association of oral candidiasis with diabetic control. J Clin Pathol 1989; 42: 502–505.

596. Samaranayake LP. Host factors and oral candidosis. In: Samaranayake, LP, MacFarlane, TW, eds. Oral Candidosis. London: Wright 1990: 66–103.

597, Soysa NS, Samaranayake LP, Ellepola AN. Diabetes mellitus as a contributory factor in oral candidosis. Diabet Med. 2006 May;23(5):455-9

598. Darwazeh AM, MacFarlane TW, MacCuish AC, Lamey PJ. Mixed salivary glucose levels and candidal carriage in patients with diabetes mellitus. J Oral Pathol Med 1991; 20: 280–283.

599. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315–1321.

600. Quirino MR, Birman EG, Paula CR. Oral manifestations of diabetes mellitus in controlled and uncontrolled patients. Braz Dent J 1995; 6: 131–136.

601. Samaranayake LP. Nutritional factors and oral candidosis. J Oral Pathol. 1986 Feb;15(2):61-5.

602. Pizzo G, Giuliana G, Milici ME, Giangreco R. Effect of dietary carbohydrates on the in vitro epithelial adhesion of Candida albicans, Candida tropicalis, and Candida krusei. New Microbiol. 2000 Jan;23(1):63-71.

603. Farthing MJG. Iron and immunity. Acta Paediatr Scand Suppl 1989;361:44-52.

604. Lu SY, Wu HC. Initial diagnosis of anemia from sore mouth and improved classification of anemias by MCV and RDW in 30 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Dec;98(6):679-85.

605. Field EA, Speechley JA, Rugman FR, Varga E, Tyldesley WR. Oral signs and symptoms in patients with undiagnosed vitamin B12 deficiency. J Oral Pathol Med. 1995 Nov;24(10):468-70

606. Jenkins WM, Macfarlane TW, Ferguson MM, Mason DK. Nutritional deficiency in oral candidosis. Int J Oral Surg. 1977 Aug;6(4):204-10.

607. Tenovuo J. Antimicrobial function of human saliva—how important is it for oral health? Acta Odontol Scand 1998;56:250-6.

608. Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol. 2006 Aug;42(7):698-702. Epub 2006 Mar 9.

609.  Diaz-Arnold AM, Marek CA. The impact of saliva on patient care: A literature review. J Prosthet Dent. 2002 Sep;88(3):337-43.

610. Narhi TO, Meurman JH, Ainamo A. Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. Drugs Aging 1999;15: 103-16.

611. Fardal O, Turnbull RS (1986). A review of the literature on useof chlorhexidine in dentistry. J Am Dent Assoc 112: 863–869.

612. Epstein JB (1990). Antifungal therapy in oropharyngeal mycotic infections. Oral Surg Oral Med Oral Pathol 69: 32–41

613. Ellepola AN, Samaranayake LP. Adjunctive use of chlorhexidine in oral candidoses: a review. Oral Dis. 2001 Jan;7(1):11-7.

614. Related Articles, Shiboski CH, Hodgson TA, Ship JA, Schiødt M. Management of salivary hypofunction during and after radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S66.e1-19

615. Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia. Head Neck. 2007 Jan;29(1):58-63

616. Related Articles, Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004 Jul 1;15(4):221-39.

617. Related Articles, Scully CDrug effects on salivary glands: dry mouth. Oral Dis. 2003 Jul;9(4):165-76.

618. Related Articles, Nagler RM, Nagler A. The molecular basis of salivary gland involvement in graft--vs.--host disease. J Dent Res. 2004 Feb;83(2):98-103.

619. Related Articles, Woo SB, Lee SJ, Schubert MM. Graft-vs.-host disease. Crit Rev Oral Biol Med. 1997;8(2):201-16.

620. Barbeau J, Séguin J, Goulet JP, Koninck L, Avon SL, Lalonde B, et al. Reassessing the presence of Candida albicans in denture related stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:51-9.

621. Odman PA. The effectiveness of an enzyme containing denture cleaner. Quintessence Int 1992;23:187–90.

622. Stafford GD, Arendorf GD, Huggett R. The effect of overnight drying and water immersion on candidal colonisation and properties of complete dentures. J Dent 1986;14:52–6.

623.

624.

625. Abu-EI Teen K, Ghannum M, Stretton RI (1989). Effects of sub-inhibitory concentrations of antifungal agents on adherence of Candida spp. to buccal epithelial cells in vitro. Mycoses 32:551-562.

626. Ellepola ANB, Samaranayake LP, Oral candidal infections and antimycotics, Crit Rev Oral Biol Med, 11(2): 172-198 (2000)

627. Lambert H, O'Grady FW (1992). Antifungal agents. In: Antibiotics and chemotherapy. Lambert H, O'Grady FW, editors. London: Churchill Livingstone, pp. 27-37.

628. Lesse Al (1995). Antifungal agents. In: Essentials of pharmacology. Smith CM, Reynard A, editors. Philadelphia: W.B. Saunders, pp. 404-411.

629. Greenspan D (1994). Treatment of oropharyngeal candidosis in HIV-positive patients. I Am Acad Dermatol 31 :S5 -S55.

630. Gombert ME, du Bouchet L, Aulicino TM, Butt KM (1987). A comparison of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. I Am Med Assoc 258:2553-2558.

631. Martin MV (1990). Antifungal agents. In: Oral candidosis. Samaranayake LP, MacFarlane TW, editors. London: Wright, pp. 238-255.

632. renciaglia MI, Ghezzi MC, Cipriani P, Mancini C, Trancassini M (1986). The influence of antifungal drugs on adhesion of C. albicans to buccal epithelial cells. Chemotherapy 5:200-203.

633. Johnson EM, Richardson MD, Warnock DW (1983). Effect of imidazole antifungals on the development of germ tubes by strains of C. albicans. J Antimicrob Chemother 12:303-316.

634. Dias AP, Samaranayake LP, Lee MT (1997). Miconazole lacquer in the treatment of denture stomatitis: clinical and microbiological findings in Chinese patients. Clin Oral Invest 1:47-52.

635. Silverman S, Gallo 1W, McKnight ML, Mayer P, deSanz S, Tan MM (1996). Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol

636. Van't Wout 1W (1996). Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur I Clin Microbiol Infect Dis 15:238-243

637. Samaranayake LP (1997). C. krusei infections and fluconazole therapy. Hong Kong Med 1 3:312-314.

638. White TC, Marr KA, Bowden RA (1998). Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382-402.

639. Dupont B, Drouhet E (1988). Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. I Med Vet Mycol 26:67-71.

640. Goodman IL, Winston DI, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl I Med 326:845-851.

641. Ninane 1, Gluckman E, Hann I, Gibson BS, Stevens RF (1994). A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur J Clin Microbiol Infect Dis 13:330337.

642. Winston DI, Chandrasekar PH, Lazarus HM, Goodman IL, Silber IL, Horowitz H, et al. (1993). Fluconazole prophylaxis of fungal infection in patients with acute leukemia. Results of a randomized placebocontrolled, double-blind, multicenter trial. Ann Intern Med 118:495-503.

643. Napier SS, MacDonald DG, Lamey Pl (1996). Cheilocandidosis in an adult. Br Dent 1 181:336 338.

644. Van Cutsem 1 (1994). Prophylaxis of Candida and  Aspergillus infections with oral administration of itra-  conazole. Mycoses 37:243-248.

645. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M (1994). Emergence of fluconazole resistant strains of C. albicans in patients with recur-rent oropharyngeal candidosis and human immunodeficiency virus infection. I Clin Microbiol 32:2092-2098.

646. Phillips P, Zemcov 1, Mahmood W, Montaner JSG, Craib  K, Clarke AM (1996). Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response  with in vitro susceptibility. AIDS 10: 1369-1376.

647. Eichel M, Just-Nubling G, Helm EB, Stille W (1996). Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses 39:102-106.

648. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG (1988). Itraconazole versus ketoconazole in the treatment of oral and esophageal candidosis in patients infected with HIV. AIDS 5:1367-1371.

649. Blatchford NR (1990). Treatment of oral candidosis with itraconazole: a review. I Am Acad Dermatol 23:565-567.  

650. ROBERT A. FROMTLING Overview of Medically Important Antifungal Azole Derivatives CLINICAL MICROBIOLOGY REVIEWS, Apr. 1988, p. 187-217

651. Espinel-Ingroff A, Boyle K, Sheehan D. In vitro antifungal activities of  voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150:101–15.

652. Theuretzbacher U, Ihle F, Derendorf H. Pharmacoki-  netic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649–63.

653. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents. 2007 Aug;30(2):108-17.

654. Law D, Moore CB, Denning DW. Activity of SCH 56592 com-  pared with those of fluconazole and itraconazole against Candida spp.  Antimicrob Agents Chemother 1997;41:2310–1.

655 Galgiani JN, Lewis ML. In vitro studies of activities of the antifungal  triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents  Chemother 1997;41:180–3.

656. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-  56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997;41:1124–6.

657. Marco F, Pfaller MA, Messer SA, Jones RN. In vitro activity of a  new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. Mycopathologia 1998;141:73–7.

658. Gonzalez GM, Fothergill AW, Sutton DA, et al. In vitro activities of  new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005;43:281–4.

659. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized  trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis  2006;42:1179–86.

660. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723–7.

661. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents. 2007 Aug;30(2):108-17

662. Nyfeler R, Keller SW. Metabolics of microorganisms. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components. Helv Chim Acta 1974;57:2459–77.

663. Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-_-d-glucan synthase inhibitors. Antimicrob Agents Chemother 2000;44:368–77.

664. Park S, Kelly R, Nielsen Kahn J, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005;49:3264–73.

665. Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:470–4.

666. Moudgal V, Little T, Bolkov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005;49:767–9.

667. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized doubleblind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294–9.

668. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, doubleblind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002;46:451–7.

669. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized doubleblind study of caspofungin versus amphotericin B for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529–35.

670. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005;21:899–907.

671. Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20:475–81.

672. deWet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, doubleblind, parallel-group, dose–response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIVpositive patients. Clin Infect Dis 2004;39:842–9.

673. Denning DW. Echinocandin antifungal drugs. Lancet. 2003 Oct 4;362(9390):1142-51.

674. Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590–8.

675. Arévalo MP, Carillo-Mu˜noz AJ, Salgado J, et al. Antifungal activity of the echinocandin anidulafungin (VER002,LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003;51:163– 6.

676. Reboli AC et al. Anidulafungin versus fluconazole for invasive candidiasis. N Eng J Med 2007;356(24):2472-82.

677. www.emea.europa.eu/humandocs/PDFs/EPAR/ecalta/H-788-fr1.pdf

678. Ryder, N. S., G. Seidl, and P. Troke. 1984. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrob. Agents Chemother. 25:483–487.

679. Ryder, N., and B. Favre. 1997. Antifungal activity and mechanism of action of terbinafine. Rev. Contemp. Pharmacother. 8:275–287.

680. Milillo L, Lo Muzio L, Carlino P, Serpico R, Coccia E, Scully C. Candida-related denture stomatitis: a pilot study of the efficacy of an amorolfine antifungal varnish. Int J Prosthodont. 2005 Jan-Feb;18(1):55-9.

681. Ghannoum MA, Elewski B Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol. 1999 Nov;6(6):921-3.

682. Hauser, D.; Sigg, H.P Isolation and decomposition of sordarin. Helv. Chim. Acta, 1971;54(4):1178-90

683. Kamai Y, Kakuta M, Shibayama T, Fukuoka T, Kuwahara S. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice. Antimicrob Agents Chemother. 2005 Jan;49(1):52-6.

684. Dominguez, J. M., V. A. Kelly, O. S. Kinsman, M. S. Marriott, F. Gomez de las Heras, and J. J. Martin. 1998. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. 42:2274–2278.

685.  Lóránd T, Kocsis B. Recent advances in antifungal agents. Mini Rev Med Chem. 2007 Sep;7(9):900-11.

686. Basilio A, Justice M, Harris G, Bills G, Collado J, de la Cruz M, Diez MT, Hernandez P, Liberator P, Nielsen kahn J, Pelaez F, Platas G, Schmatz D, Shastry M, Tormo JR, Andersen GR, Vicente F. The discovery of moriniafungin, a novel sordarin derivative produced by Morinia pestalozzioides. Bioorg Med Chem. 2006 Jan 15;14(2):560-6.

687. Budtz-Jörgensen E, Löe H. Chlorhexidine as a denture disinfectant in the treatment of denture stomatitis. Scand J Dent Res. 1972;80(6):457-64.

688. Ellepola ANB, Samaranayake LP (1999a). In vitro postantifungal effect (PAFE) elicited by chlorhexidine gluconate on oral isolates of Candida albicans. Microb Ecol Health Dis 11: 143-148.

689. McCourtie J, MacFarlane TW, Samaranayake LP (1986). A comparison of the effects of chlorhexidine gluconate, amphotericin B and nystatin on the adherence of Candida species to denture acrylic. I Antimicrob Chemother 17:575-583.

690. McCourtie J, MacFarlane TW, Samaranayake LP (1985). Effect of chlorhexidine gluconate on the adherence of Candida species to denture acrylic. J Med Microbiol 20:97-104.

691. Kamalakshi BA, Santarpia PR, Pollack I1, Renner RP (1992). Assessment of antimicrobial treatment of denture stomatitis using an in vivo replica model system: therapeutic efficacy of an oral rinse. I Prosthet Dent 67:72-77.

692. Giuliana G, Pizzo G, Milici ME, Musotto GC, Giangreco R (1997). In vitro antifungal properties of mouth rinses containing antimicrobial agents. I Periodontol 68:729-733.

693. Barkvoll P, Attramadal A (1989). Effect of nystatin and chlorhexidine gluconate on C. albicans. Oral Surg Oral Med Oral Pathol 67:279-281.

694. Pappagianis, D., M. S. Collins, R. Hector, and J. Remington. 1979. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob. Agents Chemother. 16:123-126.

695. 695.Vazquez, J. A., M. T. Arganoza, D. Boikov, S. Yoon, J. D. Sobel, and R. A. Akins. 1998. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. J. Clin. Microbiol. 36:2690–2695.
     

Retour à la table des matières.